Evidence map›Paper›PMID 39291020›Full record

ArticleACS medicinal chemistry letters2024

Structure-Activity Relationship of Oxacyclo- and Triazolo-Containing Respiratory Syncytial Virus Polymerase Inhibitors.

Minh T Tran, Sandrine Grosse, Rodrigo J Carbajo, Edgar Jacoby, Yanting Yin, Xiaodi Yu, Carol Martinez, Bart Stoops, Ludwig Cooymans, Lili Hu and 9 more

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Minh T TranJanssen Pharmaceutica NV, 2340 Beerse, Belgium.ORCID https://orcid.org/0009-0009-8047-9333
Sandrine GrosseJanssen Pharmaceutica NV, 2340 Beerse, Belgium.
Rodrigo J CarbajoJanssen Research and Development, Janssen-Cilag, S.A., C/Jarama 75, 45007 Toledo, Spain.
Edgar JacobyJanssen Pharmaceutica NV, 2340 Beerse, Belgium.
Yanting YinJohnson & Johnson Innovative Medicine, Spring House, Pennsylvania, Pennsylvania 19477, United States.
Xiaodi YuJohnson & Johnson Innovative Medicine, Spring House, Pennsylvania, Pennsylvania 19477, United States.
Carol MartinezJanssen Pharmaceutica NV, 2340 Beerse, Belgium.
Bart StoopsJanssen Pharmaceutica NV, 2340 Beerse, Belgium.
Ludwig CooymansJanssen Pharmaceutica NV, 2340 Beerse, Belgium.
Lili HuJanssen Pharmaceutica NV, 2340 Beerse, Belgium.
Ferdinand H LutterChemical Process R&D, Discovery Process Research, Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
Serge PietersJanssen Pharmaceutica NV, 2340 Beerse, Belgium.
Eric TanJanssen Pharmaceutica NV, 2340 Beerse, Belgium.
Jesus AlcázarJanssen Research and Development, Janssen-Cilag, S.A., C/Jarama 75, 45007 Toledo, Spain.
Dirk RoymansJanssen Pharmaceutica NV, 2340 Beerse, Belgium.
Herman van VlijmenJanssen Pharmaceutica NV, 2340 Beerse, Belgium.ORCID https://orcid.org/0000-0002-1915-3141
Peter RigauxJanssen Pharmaceutica NV, 2340 Beerse, Belgium.
Sujata SharmaJohnson & Johnson Innovative Medicine, Spring House, Pennsylvania, Pennsylvania 19477, United States.
Tim H M JonckersJanssen Pharmaceutica NV, 2340 Beerse, Belgium.ORCID https://orcid.org/0000-0003-3974-822X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the availability of medicines preventing respiratory syncytial virus (RSV) infection, post-exposure treatment options are needed for addressing patient's needs. RSV non-nucleoside polymerase inhibitors (NNI) have emerged as a promising asset for which our group previously disclosed JNJ-8003 with potent

Identifiers

PMID39291020
PMCPMC11403738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.